FSD Pharma announces appointment of Nathan Coyle, the company's corporate controller as its interim chief financial officer with immediate effectProactive Investors • 05/05/21
FSD Pharma Issues Important Message to Shareholders and Response to Dissident CircularBusiness Wire • 05/03/21
Concerned Shareholders Issue Information Circular for FSD Pharma Inc. Shareholders' Meeting - Urge Shareholders to Vote Their Shares Using the Gold ProxyNewsfile Corp • 04/27/21
FSD Pharma throws resources behind legacy anti-inflammatory drug as potential coronavirus therapyProactive Investors • 04/22/21
FSD Pharma Inc. Management Wasting Company Money by Seeking to Further Delay Shareholder MeetingPRNewsWire • 04/05/21
FSD Pharma in license agreement with Innovet Italia to develop FDA-approved drugs to treat gastrointestinal diseases in dogs and catsProactive Investors • 03/17/21
FSD Pharma Enters into License Agreement to Develop FDA approved Veterinary Drugs for the Treatment of Gastro-Intestinal Diseases in Dogs and CatsBusiness Wire • 03/17/21
Court Orders FSD Pharma to Move Shareholder Meeting Date to May 14, 2021, Imposes Requirement of an Independent Meeting Chair and Prevents Dr. Raza Bokhari and Other Directors from Voting Recently Issued SharesNewsfile Corp • 03/08/21
FSD Pharma signs agreement covering the sale of Class B shares on an 'at-the-market' basisProactive Investors • 02/11/21
FSD Pharma Announces First Patient Randomized in Phase 2 Trial of FSD201 for the Treatment of Hospitalized Patients with COVID-19Business Wire • 12/15/20